Cargando…

Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma

OBJECTIVE. While a certain fraction of endometriomas can develop de novo epithelial ovarian cancer (EOC) such as clear cell carcinoma (OCCC), there is currently no useful biomarker available for early detection of OCCC from endometriomas. The aim of this study was to describe the diagnostic utility...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikami, Mikio, Tanabe, Kazuhiro, Matsuo, Koji, Miyazaki, Yuko, Miyazawa, Masaki, Hayashi, Masaru, Asai, Satoshi, Ikeda, Masae, Shida, Masako, Hirasawa, Takeshi, Kojima, Nozomi, Sho, Ryuichiro, Iijima, Sadayo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528864/
https://www.ncbi.nlm.nih.gov/pubmed/26477941
http://dx.doi.org/10.1016/j.ygyno.2015.10.012
_version_ 1783589339178991616
author Mikami, Mikio
Tanabe, Kazuhiro
Matsuo, Koji
Miyazaki, Yuko
Miyazawa, Masaki
Hayashi, Masaru
Asai, Satoshi
Ikeda, Masae
Shida, Masako
Hirasawa, Takeshi
Kojima, Nozomi
Sho, Ryuichiro
Iijima, Sadayo
author_facet Mikami, Mikio
Tanabe, Kazuhiro
Matsuo, Koji
Miyazaki, Yuko
Miyazawa, Masaki
Hayashi, Masaru
Asai, Satoshi
Ikeda, Masae
Shida, Masako
Hirasawa, Takeshi
Kojima, Nozomi
Sho, Ryuichiro
Iijima, Sadayo
author_sort Mikami, Mikio
collection PubMed
description OBJECTIVE. While a certain fraction of endometriomas can develop de novo epithelial ovarian cancer (EOC) such as clear cell carcinoma (OCCC), there is currently no useful biomarker available for early detection of OCCC from endometriomas. The aim of this study was to describe the diagnostic utility of a novel biomarker for EOC especially for OCCC to distinguish from endometrioma. METHODS. More than 100,000 glycan structures of serum glycoproteins obtained from 134 pretreatment all stage EOC patients (including 45 OCCCs) and 159 non-cancer control women (including 36 endometriomas) were explored for a mass spectrum approach. Diagnostic accuracy of identified biomarker was compared to the one of CA-125 by comparing area under curve (AUC) and positive/negative predictive values (PPV and NPV). RESULTS. A2160, a fully-sialylated alpha-chain of complement 4-binding protein, was identified as a candidate target marker. A2160 was significantly elevated in all stages of OCCC compared to with endometriomas. Diagnostic accuracy of A2160 (cutoff 1.6 U/mL) to distinguish early stage OCCC from endometrioma is significantly higher than that of CA-125 (cutoff 35 IU/L): AUC for A2160 versus CA-125,0.92 versus 0.67; PPV 95% versus 64%; and NPV 85% versus 58%. In addition, fully-sialylated glycans had a higher accuracy for diagnosing EOC as compared to partially-sialylated glycans of alpha-chain of complement 4-binding protein. CONCLUSION. Our study suggested that A2160 may be a useful biomarker to distinguish early-stage OCCC from endometrioma. This new biomarker can be potentially applied for the monitoring of endometrioma patients, making possible the early diagnosis of OCCC.
format Online
Article
Text
id pubmed-7528864
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-75288642020-10-01 Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma Mikami, Mikio Tanabe, Kazuhiro Matsuo, Koji Miyazaki, Yuko Miyazawa, Masaki Hayashi, Masaru Asai, Satoshi Ikeda, Masae Shida, Masako Hirasawa, Takeshi Kojima, Nozomi Sho, Ryuichiro Iijima, Sadayo Gynecol Oncol Article OBJECTIVE. While a certain fraction of endometriomas can develop de novo epithelial ovarian cancer (EOC) such as clear cell carcinoma (OCCC), there is currently no useful biomarker available for early detection of OCCC from endometriomas. The aim of this study was to describe the diagnostic utility of a novel biomarker for EOC especially for OCCC to distinguish from endometrioma. METHODS. More than 100,000 glycan structures of serum glycoproteins obtained from 134 pretreatment all stage EOC patients (including 45 OCCCs) and 159 non-cancer control women (including 36 endometriomas) were explored for a mass spectrum approach. Diagnostic accuracy of identified biomarker was compared to the one of CA-125 by comparing area under curve (AUC) and positive/negative predictive values (PPV and NPV). RESULTS. A2160, a fully-sialylated alpha-chain of complement 4-binding protein, was identified as a candidate target marker. A2160 was significantly elevated in all stages of OCCC compared to with endometriomas. Diagnostic accuracy of A2160 (cutoff 1.6 U/mL) to distinguish early stage OCCC from endometrioma is significantly higher than that of CA-125 (cutoff 35 IU/L): AUC for A2160 versus CA-125,0.92 versus 0.67; PPV 95% versus 64%; and NPV 85% versus 58%. In addition, fully-sialylated glycans had a higher accuracy for diagnosing EOC as compared to partially-sialylated glycans of alpha-chain of complement 4-binding protein. CONCLUSION. Our study suggested that A2160 may be a useful biomarker to distinguish early-stage OCCC from endometrioma. This new biomarker can be potentially applied for the monitoring of endometrioma patients, making possible the early diagnosis of OCCC. 2015-10-18 2015-12 /pmc/articles/PMC7528864/ /pubmed/26477941 http://dx.doi.org/10.1016/j.ygyno.2015.10.012 Text en This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Mikami, Mikio
Tanabe, Kazuhiro
Matsuo, Koji
Miyazaki, Yuko
Miyazawa, Masaki
Hayashi, Masaru
Asai, Satoshi
Ikeda, Masae
Shida, Masako
Hirasawa, Takeshi
Kojima, Nozomi
Sho, Ryuichiro
Iijima, Sadayo
Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma
title Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma
title_full Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma
title_fullStr Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma
title_full_unstemmed Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma
title_short Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma
title_sort fully-sialylated alpha-chain of complement 4-binding protein: diagnostic utility for ovarian clear cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528864/
https://www.ncbi.nlm.nih.gov/pubmed/26477941
http://dx.doi.org/10.1016/j.ygyno.2015.10.012
work_keys_str_mv AT mikamimikio fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT tanabekazuhiro fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT matsuokoji fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT miyazakiyuko fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT miyazawamasaki fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT hayashimasaru fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT asaisatoshi fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT ikedamasae fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT shidamasako fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT hirasawatakeshi fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT kojimanozomi fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT shoryuichiro fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma
AT iijimasadayo fullysialylatedalphachainofcomplement4bindingproteindiagnosticutilityforovarianclearcellcarcinoma